Daniel Pella
A5088396929- Lipoproteins and Cardiovascular Health
- Nutritional Studies and Diet
- Fatty Acid Research and Health
- Blood Pressure and Hypertension Studies
- Diet and metabolism studies
- Coenzyme Q10 studies and effects
- Romani and Gypsy Studies
- Health Systems, Economic Evaluations, Quality of Life
- Heart Rate Variability and Autonomic Control
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Consumer Attitudes and Food Labeling
- Obesity, Physical Activity, Diet
- Liver Disease Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Diet, Metabolism, and Disease
- Hepatitis C virus research
- Cardiovascular Function and Risk Factors
- Cardiovascular Syncope and Autonomic Disorders
- Antiplatelet Therapy and Cardiovascular Diseases
- Autopsy Techniques and Outcomes
- Microbial Metabolism and Applications
- Global Public Health Policies and Epidemiology
- Cardiovascular Disease and Adiposity
- Heart rate and cardiovascular health
- Cholesterol and Lipid Metabolism
University of Pavol Jozef Šafárik
2015-2024
Medical University of Lodz
2020-2024
Ocná klinika
2021
Slovak Public Health Association
2020
University clinical center of Republika Srpska
2020
St Thomas' Hospital
2020
King's College London
2020
Polish Mother’s Memorial Hospital Research Institute
2020
University of Zielona Góra
2020
Univerzitná Nemocnica Louisa Pasteura
2011-2018
Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, inflammatory hypothesis atherothrombosis has remained unproved.We conducted a randomized, double-blind trial canakinumab, therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction high-sensitivity C-reactive protein level 2 mg or more per liter. The compared three doses canakinumab...
Elevated lipoprotein-associated phospholipase A2 activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma levels this enzyme are associated with an increased risk coronary events. Darapladib is a selective oral inhibitor A2.In double-blind trial, we randomly assigned 15,828 patients stable heart disease to receive either once-daily darapladib (at dose 160 mg) or placebo. The primary end point was composite cardiovascular death, myocardial infarction,...
a unified definition of statin intolerance, and to complement the recent EAS statement on SAMS, where pathophysiology, diagnosis management were comprehensively presented.
1.1. Cardiovascular disease and dyslipidemia: prevalence global economic impact Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide, reaching 31% deaths in 2012 [1]. In particular, atherosclerosis ischemic heart (IHD) main causes premature death Europe responsible for 42% women 38% men under 75 years old [2]. The impact CVD is estimated to have been US $906 billion 2015 expected rise by 22% 2030 [3]. also represent major disability developed countries. It has that...
Statins are one of the most commonly prescribed drugs in clinical practice. They usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy muscle-related. The recent statement European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), avoided use term 'statin intolerance'. Although syndromes common observed after therapy, excluding other side might underestimate number patients intolerance,...
Proteins play a crucial role in metabolism, maintaining fluid and acid-base balance antibody synthesis. Dietary proteins are important nutrients classified into: 1) animal (meat, fish, poultry, eggs dairy), and, 2) plant (legumes, nuts soy). modification is one of the most lifestyle changes that has been shown to significantly decrease risk cardiovascular (CV) disease (CVD) by attenuating related factors. The CVD burden reduced optimum diet through replacement unprocessed meat with low...
Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors to morbidity mortality across Europe. Much of these diseases burden is modifiable, in particular by lipid-lowering therapy (LLT). Current guidelines based on the sound premise that with respect low density lipoprotein cholesterol (LDL-C), "lower better for longer", recent data have strongly emphasized need also "the earlier better". In addition statins, which been...
The objective of the study was to find out prevalence overweight, obesity, undernutrition and physical activity status in urban populations India. Cross-sectional surveys were conducted 6-12 streets each five cities different regions India using a common protocol criteria diagnosis.A total 6940 subjects (3433 women 3507 men) aged 25 years above randomly selected from Moradabad (n = 2002),Trivandrum 1602), Calcutta 900), Nagpur 894) Bombay 1542). Evaluation validation performed by physician...
Background There are few studies detailing the prevalence of prehypertension and hypertension in India.Methods Men women, over 25 years age were included. After completion a dietitian-administered questionnaire followed evaluation by physician, physical examination blood pressure measurement. Cross-sectional survey screened 6940 subjects, (3507 men (M), 3433 women (W): 1993-96) from cities located five corners India (Kolkata, n = 900; Nagpur, 894; Mumbai, 1542; Thiruanantpuram, 1602;...
Assess the risk of ischaemic events associated with psychosocial stress in patients stable coronary heart disease (CHD).Psychosocial was assessed by a questionnaire 14 577 (median age 65.0, IQR 59, 71; 81.6% males) CHD on optimal secondary preventive therapy prospective randomized STABILITY clinical trial. Adjusted Cox regression models were used to assess associations between individual stressors, baseline cardiovascular factors and outcomes.After 3.7 years follow-up, depressive symptoms,...
Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors to morbidity mortality across Europe. Fortunately, as much two thirds of this disease's burden is modifiable, in particular by lipid-lowering therapy (LLT). Current guidelines based on the sound premise that, with respect low-density lipoprotein cholesterol (LDL-C), "lower better for longer", recent data have strongly emphasised need also "the earlier better". In addition...